⚕ GalenOps field
←

718-1371

completed

Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
718 (USA) · Dr. Nolan
consented 2013-04-26

AEs
6
Serious
1
Dropout signal
–

Adverse events

mild assessed

Mild APPLICATION SITE IRRITATION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-05-24 (study day 29.0); relationship: PROBABLE

moderate assessed

Moderate APPLICATION SITE IRRITATION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-05-24 (study day 29.0); relationship: PROBABLE

mild assessed

Mild FATIGUE — outcome: RECOVERED/RESOLVED; onset 2013-05-09 (study day 14.0); relationship: POSSIBLE

moderate assessed

Moderate HALLUCINATION, VISUAL — outcome: RECOVERED/RESOLVED; onset 2013-06-02 (study day 38.0); relationship: POSSIBLE

mild assessed

Mild NAUSEA — outcome: RECOVERED/RESOLVED; onset 2013-05-09 (study day 14.0); relationship: POSSIBLE

severe serious reported

Severe PARTIAL SEIZURES WITH SECONDARY GENERALISATION — outcome: RECOVERED/RESOLVED; onset 2013-06-02 (study day 38.0); relationship: NONE; serious criteria: hospitalization

Data queries

No data queries.